Background -An abnormal platelet release of oxygen-free radicals has been described in acetylsalicylic acid (aspirin)-induced asthma, a finding which might suggest the existence of an intrinsic, specific platelet abnormality of arachidonic acid metabolism in these patients. The objective of this study was to evaluate platelet arachidonic acid metabolism in asthmatic patients with or without intolerance to aspirin. Methods -Thirty subjects distributed into three groups were studied: group 1, 10 healthy subjects; group 2, 10 asthmatic patients with aspirin tolerance; and group 3, 10 aspirin-intolerant asthmatics. Platelets were isolated from blood, preincubated with 3H-arachidonic acid for 30 minutes and then incubated for 10minutes with platelet activating factor (PAF) and aspirin. Cyclo-oxygenase (thromboxane, PGE2, PGF2a, and HHT) and lipoxygenase (12-HETE) arachidonic acid metabolites were measured by high pressure liquid chromatography. Release of oxygen free radicals after incubation with PAF and aspirin was measured by chemiluminescence. Platelet levels of glutathione peroxidase (GSH-Px) were also measured using spectrophotometry. Results -Platelets from aspirin-intolerant asthmatic patients produced higher quantities of arachidonic acid metabolites than the control group at baseline conditions. This increase was significant only for lipoxygenase products. No differences were found amongst the three groups in the response of arachidonic acid metabolism to PAF and aspirin. Incubation with aspirin but not with PAF caused an increase in oxygen-free radical production in aspirin-intolerant patients whereas in aspirin-tolerant patients PAF, rather than aspirin, was the more potent stimulus for oxygen-free radical production. No differences in GSH-Px levels were found amongst the three groups.
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Conclusions -These results suggest that the platelet lipoxygenase pathway is activated in aspirin-intolerant patients and that the production ofoxygen-free radicals may differentiate aspirin-tolerant from aspirin-intolerant asthmatic subjects. Our study, however, does not support the hypothesis that an increase in lipoxygenase products may be responsible for oxygenfree radical production. Moreover, a lowered platelet GSH-Px activity does not seem to be involved in this phenomenon. (Thorax 1995; 50:490-496) Keywords: bronchial asthma, aspirin-sensitive asthma, oxygen-free radicals, arachidonic acid metabolites, glutathione peroxidase.
In some asthmatic patients acetylsalicylic acid (aspirin) and other non steroidal anti-inflammatory drugs (NSAIDs) precipitate asthma attacks. "A Although during the last two decades numerous studies have been carried out to investigate this phenomenon, the mechanism(s) responsible remains unknown. Szczeklik et a15 showed that all drugs that share the common property of inhibiting the cyclooxygenase pathway can provoke asthma attacks. This finding has suggested that, in aspirin-induced asthma, blockade of the cyclooxygenase enzyme might divert arachidonic acid metabolism from the cyclo to the lipoxygenase pathway, leading to both an excessive production of bronchoconstrictor leukotrienes as well as a lack of bronchodilator PGE,.13 It has also been proposed that aspirin intolerance is the consequence of viral infection,6 but this hypothesis has yet to be substantiated by any experimental evidence. A recent study has shown a significant rise in urinary LTE4 levels after aspirin ingestion in aspirin-sensitive patients.7 Picado et al8 have also reported that intranasal challenge with lysine-aspirin is associated with an increased concentration of peptide leukotrienes in nasal lavage in aspirin-sensitive subjects. The demonstration of increased leukotriene release in aspirin-induced asthma suggests that peptide leukotrienes have a role in the pathogenesis of aspirin sensitivity. The cellular source for the augmented leukotriene production is still unknown.
Although the role of platelets in aspirininduced asthma is a matter of debate, some recent findings suggest that these cells might be involved in this peculiar clinical syndrome. Ameisen et al910 have described an abnormal platelet release of oxygen-free radicals from aspirin-sensitive asthmatics exposed to aspirin in vitro -a finding that might suggest the existence of an intrinsic, specific platelet abnormality of arachidonic acid metabolism in these patients. Recent studies have also shown lowered glutathione peroxidase (GSH-Px) activity in platelets of aspiinn-sensitive asthmatics" 12 and, since GSH-Px plays an important part in the protection against oxidative damage,13-l5 it has been suggested that aspirinrelated asthma attacks are due in part to a deficit in this scavenger." '12 On the other hand, although no consistent abnormality in arachidonic acid metabolism has ever been shown in aspirin-sensitive patients, it seems reasonable to suspect that the abnormal response ofa patient's platelets to NSAIDs is due to a change in the balance of arachidonic acid metabolism. If this hypothesis was true we might expect a different pattern of release of arachidonic acid metabolites from the platelets of aspirin-sensitive patients compared with both aspirin-insensitive asthmatics and healthy subjects.
Because release of oxygen-free radicals can occur after activation of both the cyclo and lipoxygenase pathways, we reasoned that aspirin must increase the production of oxygenfree radicals in aspirin-intolerant asthmatic subjects by increasing the activity of either one or both pathways. In order to assess this potential aspirin action we compared the effects ofaspirin with platelet activating factor (PAF), a well known potent platelet activator.
It is interesting to note that the three postulated intrinsic platelet abnormalities (excessive production of oxygen-free radicals, lowered GSH-Px activity, and an increased production of lipoxygenase metabolites) have never been evaluated in a study designed to assess their interrelation in the pathogenesis of aspirin-induced idiosyncratic reactions. The aim of this study was to evaluate these abnormalities and their possible relationship in the origin of aspirin-induced asthma.
Mean (SD) characteristics of subjects The three groups were similar in age and sex distribution. As expected, the proportion of aspirin-intolerant patients suffering from nasal polyps was higher than in the aspirin-tolerant group. Severity of disease was assessed according to a score taking into account clinical symptoms (score 1-3), severity of bronchial obstruction measured by forced spirometry (score 1-4), and the amount of treatment needed to control symptoms (score 1-3). There were no differences between tolerant and intolerant patients with respect to either clinical score or bronchial obstruction. A higher proportion of aspirin-intolerant patients received treatment with inhaled steroids, but the difference was not significant. None of them, however, were on oral steroid treatment. PLATELET 
ISOLATION
Between 08.30 and 09.30 hours a 30 ml specimen of blood was drawn from the antecubital vein of each of the 30 subjects. Platelet-rich plasma was obtained by a method previously described by Levine and Fedorko'6 and modified by Rao et al. '7 Briefly, whole blood was centrifuged at 225 g for 15 minutes at 37°C. In order to discard anomalous platelets and previous ingestion of any antiaggregant substance, aggregation studies were performed by adding arachidonic acid to 450 pl platelet-rich plasma according to Born taken together) than the cyclo-oxygenase pathway (a 20% increase in TXB2, PGE,, PGF2,,, and HHT production for the three groups) (p<0000 1).
Response to aspirin
Aspirin caused the least quantitative changes and none of these changes reached statistical significance (fig 4) . No differences in the production of lipoxygenase metabolites were detected among the three groups after incubation with aspirin.
PLATELET CHEMILUMINESCENCE For technical reasons only nine patients from each group were studied. PAF and aspirininduced platelet chemiluminescence at different doses is presented in fig 5. Platelets from aspirin-sensitive patients showed the maximal burst of chemiluminescence after being incubated with 40 itl aspirin. The addition of different doses of aspirin to platelets from healthy and aspirin-tolerant asthmatic subjects produced a mild and non-significant increase in light emission whereas in aspirin-intolerant asthmatics a moderate and significant response in light emission was detected with 40 pl aspirin. Although aspirin-intolerant patients showed higher chemiluminescence values than the other two groups, the difference was not significant. Only three of the nine aspirinintolerant patients, however, showed a marked increase in chemiluminescence. PAF produced a considerable increase in light emission in aspirin-tolerant patients and healthy subjects. However, in contrast to aspirin, PAF had no effect in aspirin-intolerant patients. In aspirin-tolerant patients 25 ,u and 50 1d PAF significantly increased chemi- luminescence (p<0005). The light emission response was also statistically significant with 50,u1 PAF in healthy subjects (p<0005). In aspirin-intolerant patients the increase in light emission after incubation with 40 VI aspirin was significantly higher than after incubation with PAF (50,l) (p<005).
GSH-Px ACTIVITY For technical reasons only eight subjects from each group were studied. The mean (SD) results of the GSH-Px assay were 369-6 (82) mU x 109/platelet in controls (group 1); 340-6 (64) mU x 1 09/platelet in aspirin-tolerant asthmatics (group 2); and 330-8 (58) mU x 109/ platelet in aspirin intolerant asthmatics (group 3) (fig 6) . No significant differences in GSHPx determinations were found either between healthy and asthmatic subjects, or between both groups of patients.
Discussion
There were three major findings in this study. Firstly, platelet arachidonic acid metabolism was more active in aspirin-intolerant patients than in both aspirin-tolerant and healthy subjects. Secondly, no differences in the response of arachidonic acid metabolism to either aspirin or PAF were found among the three groups and, finally, incubation with aspirin but not with PAF caused an increase in light emission in aspirin-intolerant patients whereas in aspirintolerant patients PAF rather than aspirin was the more potent stimulus for oxygen-free radical production. The overproduction of arachidonic acid metabolites detected in our study could result from an actual increase in the release of these products, but may also be the consequence of differences in the kinetics of the release of these metabolites between aspirin-intolerant patients and aspirin-tolerant and healthy subjects. The method used in this study (single time point) does not allow this question to be answered. Only a kinetic analysis with different substrate concentrations would allow us to elucidate the cause of the overactivity of the arachidonic acid pathway in aspirin-intolerant patients.
The mechanism responsible for the different response in light emission between aspirinintolerant and aspirin-tolerant patients to aspirin and PAF is also unclear, but our findings suggest the presence of two binding sites for PAF -a phenomenon recently described in eosinophils.2223 In these cells occupation of the high affinity PAF receptor correlates with prostanoid release whereas occupancy of the low PAF receptor is associated solely with the generation of ORL. In our study we did not defect differences in prostanoid release after PAF stimulation among the three groups; the same stimuli, however, increased the production of oxygen-free radicals in aspirin-tolerant patients and healthy subjects but not in aspirin-intolerant asthmatic patients. This phenomenon suggests the possible existence in platelets, as in eosinophils, of two PAF receptors and that in aspirin-intolerant asthmatic subjects the low affinity PAF receptor is downregulated for unknown reasons. Our results reinforce previous findings which suggest that the production of oxygen-free radicals may differentiate aspirin-tolerant from aspirin-intolerant asthmatics. Although Ameisen et al9 have suggested that the increased oxygen-free radical production by aspirin in aspirinintolerant patients is caused by the generation of lipoxygenase metabolites, our results do not support this hypothesis. Similarly, Nizankowska et al24 could not detect differences in the production of 1 2-HETE between healthy subjects and NSAID-intolerant patients after aspirin provocation.
The second hypothesis suggests that the supposed specific abnormality of arachidonic acid metabolism is localised in the cyclo-oxygenase pathway. Exogenous arachidonic acid is rapidly transformed by platelets into the prostaglandin endoperoxide PGG2. This metabolic step is catalysed by cyclo-oxygenase. PGG2 is a very short lived compound which is rapidly transformed into PGH2 via a hydroperoxidase. . These results suggest that aspirin-induced asthma might not be merely the consequence of a cyclo-oxygenase blockade, as previously proposed, and that an ongoing synthesis of PGH2, and the interaction of PGH2 with its platelet receptor, might play a part in aspirin-induced asthma.'0
We only detected an increased production of oxygen-free radicals in 33% of our aspirinintolerant patients, a figure which contrasts with the study of Ameisen et al9 who found a 100% positive aspirin-specific increase in the generation of oxygen-free radicals after stimulation of platelets from aspirin-sensitive patients. Other authors, however, have also failed to demonstrate this universal response of aspirin-sensitive patients.2 13 In keeping with Stone et al28 we were unable to detect differences in platelet GSH-Px activity between asthmatic and healthy subjects. These findings contrast with those of Hasselmark et al13 who found significantly lower GSH-Px activity in patients with intrinsic asthma than in a control group. Pearson and Suarez-Mendez'2 also found that the mean platelet GSH-Px activity was significantly lower in subjects with aspirin-induced asthma than in a healthy control group. Nevertheless, this difference could not be detected between aspirin-tolerant asthmatics and the control group. Clinical differences may account for the discrepancy in these results.
A more active disease is probably associated with an increased production of reactive oxygen radicals which may inactivate the GSH-Px. This hypothesis is supported by the observation of Bibi et al29 who demonstrated a close correlation between asthma severity and erythrocyte GSH-Px activity. They found that GSHPx levels were significantly lower during exacerbation of asthma than during stable clinical conditions. Similarly, Pearson and SuarezMendez12 also observed that platelet GSH-Px activity was lower in patients with symptoms of severe asthma than in those with mild disease. We think that the platelet GSH-Px activity of our patients and healthy subjects did not differ because only mild asthmatics were included in the study. Moreover, asthmatics studied by Malmgren et alll were not receiving any kind of treatment, while our patients and those in the study by Stone et al25 were treated with inhaled steroids (some of the latter were also receiving oral steroids). The possible effects of these treatments on platelet levels of GSH-Px cannot be overlooked.
In summary, our study shows a different in vitro response to aspirin and PAF of platelets from aspirin-tolerant and aspirin-intolerant asthmatic subjects. These results support previous findings suggesting that the production of oxygen-free radicals by platelets may differentiate aspirin-tolerant from aspirin-intolerant patients. Although the mechanisms involved in this response are unclear, our study does not support the presumed increase in lipoxygenase metabolites by inhibition of the cyclo-oxygenase pathway as the cause of oxygen-free radical production. Reduced platelet GSH-Px activity does not seem to be responsible for the pathogenesis of this intriguing phenomenon. 
